Drug treatment in heart failure
BMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7243.1188 (Published 29 April 2000) Cite this as: BMJ 2000;320:1188
- Eva Lonn, associate professor of medicine (lonnem@fhs.McMaster.ca),
- Robert McKelvie
- Hamilton Health Sciences Corporation, General Site, McMaster Clinic, Hamilton, Ontario L8L 2X2, Canada
- Correspondence to: E Lonn
Heart failure represents a complex clinical syndrome characterised by abnormalities of left ventricular function and neurohormonal regulation, exercise intolerance, shortness of breath, fluid retention, and reduced longevity.1 Despite improvements in treatment the prognosis for patients with heart failure remains poor: the risk of death annually is 5%-10% in patients with mild symptoms and 30%-40% in those with advanced disease.2 3 This condition is also associated with major morbidity and healthcare expenditure, being responsible for about 5% of hospital admissions in the United Kingdom.4
Box 1: Treatment of heart failure
Aims
Relief of symptoms
Improvement in quality of life
Prevention of admissions to hospital, recurrent ischaemic events, and further deterioration in left ventricular function
Reduction in mortality
Treatment modalities
Non-pharmacological treatments, such as exercise rehabilitation, dietary and psychological interventions, and patient education including self care strategies
Non-pharmacological treatments, such as exercise rehabilitation, dietary and psychological interventions, and patient education including self care strategies
Surgical and device based interventions
Mitral valve surgery
Coronary revascularisation
Surgical ventricular remodelling procedures
Cardiomyoplasty
Dual chamber pacing
Implantable cardioverter defibrillator treatment
Ventricular assist devices
Artificial heart
Heart transplantation
This review deals only with pharmacological treatments in chronic heart failure. Non-pharmacological measures apply to all patients, whereas surgical and device treatments (many still experimental) apply only to specific patient subsets. Patients with clinical symptoms of heart failure but normal or near normal left ventricular systolic function often have impaired left ventricular diastolic function. This heterogeneous group has been generally excluded from heart failure trials. We do not discuss the treatment of diastolic left ventricular dysfunction or acute heart failure syndromes: more comprehensive reviews are available.5
Summary points
The prognosis for patients with heart failure remains poor
Drugs clearly shown to improve survival in patients with heart failure are ACE inhibitors and βblockers
These drugs should be used in most patients with heart failure but require …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £157 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£30 / $37 / €33 (excludes VAT)
You can download a PDF version for your personal record.